Predicting erythroid response to recombinant erythropoietin plus granulocyte colony-stimulating factor therapy following a single subcutaneous bolus in patients with myelodysplasia

Haematologica

Volumn 91, Issue 5, 2006, Pages 709-710

  Bowen, David ^a,f   Hyslop, Ann ^a   Keenan, Norene ^a   Groves, Michael ^a   Culligan, Dominic ^b   Johnson, Peter ^c   Shaw, Ann ^b   Geddes, Fiona ^c   Evans, Patricia ^d   Porter, John ^d   Cavill, Ivor ^e  

^a NINEWELLS HOSPITAL   (United Kingdom)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e CARDIFF UNIVERSITY   (United Kingdom)

^f LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Erythropoietin; G CSF; Myelodysplasia; Prediction; Response

Indexed keywords

HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRANSFERRIN RECEPTOR;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; ERYTHROID CELL; ERYTHROPOIESIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; ERYTHROPOIESIS; ERYTHROPOIETIN, RECOMBINANT; FERRITINS; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; IRON; MYELODYSPLASTIC SYNDROMES; PREDICTIVE VALUE OF TESTS; RECEPTORS, TRANSFERRIN; RECOMBINANT PROTEINS; RETICULOCYTE COUNT; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 33744495322     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003;120:1037-46.
2. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671-4.
3. Bowen D, Ehmer B, Neubert F, Lewis T, Jacobs A. The clearance of a single i.v. bolus of recombinant human erythropoietin from the serum of patients with myelodysplastic syndromes and its effects on erythropoiesis. Exp Hematol 1991;19:613-6.
4. Garypidou V, Verrou E, Vakalopoulou S, Perifanis V, Tziomalos K, Venizelos I. Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. Br J Haematol 2003;123:958.
5. Musto P, Falcone A, Sanpaolo G, Bodenizza C, La Sala A, Perla G et al. Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. Br J Haematol 2003;122:269-71.